Any feedback?
Literature summary for 1.1.1.44 extracted from
- Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming (2018), Biochem. Biophys. Res. Commun., 498, 912-917 .
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | P52209 | - |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| anaplastic thyroid cancer cell | - |
Homo sapiens | - |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| 6-phosphogluconate dehydrogenase | - |
Homo sapiens |
| 6PGD | - |
Homo sapiens |
General Information
| General Information | Comment | Organism |
|---|---|---|
| drug target | the enzyme is critically involved in the development of anaplastic thyroid carcinoma resistance to oxorubicin. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming | Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
